Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).
Lagos
R
R
Centro para Vacunas en Desarrollo-Chile.
Avendaño
A
A
Prado
V
V
Horwitz
I
I
Wasserman
S
S
Losonsky
G
G
Cryz
S
S
Kaper
J B
JB
Levine
M M
MM
D000017:ABO Blood-Group System; D000907:Antibodies, Bacterial / Q000276:immunology*; D001770:Blood Bactericidal Activity; D002648:Child; D002677:Chile; D002771:Cholera / Q000276:immunology / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D006801:Humans; D014613:Vaccines, Attenuated / Q000276:immunology; D014734:Vibrio cholerae / Q000276:immunology*
D000017:ABO Blood-Group System; D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D014613:Vaccines, Attenuated